Bidirectional double-drug eluting stent and preparation method thereof

An eluting stent and dual-drug technology, applied in the field of eluting stents, can solve problems such as lumen loss, stent thrombosis, and stent stenosis, and achieve the effects of accelerating re-endothelialization, rapid endothelialization, and delayed endothelialization

Inactive Publication Date: 2018-06-05
SOUTHWEST JIAOTONG UNIV
View PDF8 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

If new atherosclerosis occurs after drug-eluting stent implantation, it may cause in-stent thrombosis due to atheroma plaque instability and intimal rupture at any per

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bidirectional double-drug eluting stent and preparation method thereof
  • Bidirectional double-drug eluting stent and preparation method thereof
  • Bidirectional double-drug eluting stent and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] The selected base stent is a cobalt alloy stent, and a solution with the following components is configured: the carrier material is polylactic acid, the solvent of atorvastatin is a mixed solvent of acetone and ether (mass ratio 2:8), and the solvent of tacrolimus is chloroform Mixed solvent with ethanol (mass ratio 1:1).

[0024] Polylactic acid (Mn=50000) 0.1g

[0025] Atorvastatin 1mg

[0026] Tacrolimus 20mg

[0027] Acetone 20ml + ether 80ml

[0028] Chloroform 50ml+ and ethanol 50ml

[0029] Mix the above systems separately and stir at 10 rpm to form a solution.

[0030] Clean the cobalt alloy stent and place it on an ultrasonic atomization sprayer. First, spray the atorvastatin / polylactic acid solution on the inside of the stent. The ultrasonic power is 0.1W, the solution flow rate is 0.01ml / min, and the number of sprays is 10 times. Finish drying at room temperature for 0.1 hour, and then spray tacrolimus / polylactic acid solution on the outside of the sten...

Embodiment 2

[0032] The selected substrate stent is a cobalt alloy stent, and a solution with the following components is configured: the carrier material is polylactic acid, the solvent of atorvastatin is a mixed solvent of acetone and ether (mass ratio 2:8), and the solvent of emodin is chloroform.

[0033]

[0034] Mix the above systems separately and stir at 300rpm to form a solution.

[0035] Clean the cobalt alloy stent and place it on an ultrasonic atomization sprayer. First, spray the atorvastatin / polylactic acid solution on the inside of the stent. The ultrasonic power is 20W, the solution flow rate is 0.5ml / min, and the number of sprays is 20 times. The spraying is completed. Dry at room temperature for 4 hours, and then use an ultrasonic atomization sprayer to spray the emodin / polylactic acid solution on the outside of the bracket. The ultrasonic power is 20W, the solution flow rate is 0.1ml / min, and the number of sprays is 30 times. After spraying, put the bracket on the Vac...

Embodiment 3

[0037] The selected base stent is a magnesium alloy stent, and a solution with the following components is configured: the carrier material of fluvastatin is polylactic acid-glycolic acid copolymer, and the solvent of fluvastatin is a mixed solvent of tetrahydrofuran and ether (mass ratio 9:1); The carrier material of mycin is polyglycolic acid, and the solvent is acetone.

[0038]

[0039] Mix the above systems separately and stir at 600rpm to form a solution.

[0040] Clean the magnesium stent and place it on an ultrasonic atomization sprayer. First, spray the fluvastatin / polylactic acid-glycolic acid copolymer solution on the inside of the stent. The ultrasonic power is 10W, the solution flow rate is 0.1ml / min, and the number of sprays is 40 times. After spraying, dry at room temperature for 4 hours, and then use an ultrasonic atomization sprayer to spray the rapamycin / polyglycolic acid solution on the outside of the bracket. The ultrasonic power is 10W, the solution flo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Thicknessaaaaaaaaaa
Thicknessaaaaaaaaaa
Login to view more

Abstract

The invention relates to a bidirectional double-drug eluting stent and a preparation method thereof. The bidirectional double-drug eluting stent is used for carrying out percutaneous coronary intervention operations so as to supply expansion support to heart and blood vessels of a patient. An A drug layer containing a drug capable of inhibiting the proliferation of smooth muscles is applied to theouter side surface, namely the surface in contact with an inner surface of a blood vessel after mounting, of the stent; and a B drug layer containing a drug capable of accelerating the reendothelialization of the blood vessel and stabilizing or reversing plaques is applied to the side surface, namely the surface deviated from the inner surface of the blood vessel after mounting, of the stent. According to the bidirectional double-drug eluting stent, the cell proliferation of the smooth muscles can be inhibited, so that the in-stent restenosis and the rapid endothelialization are inhibited, the plaques can be stabilized and reversed, the new atherosclerosis is prevented, and the occurring risk of later-period thrombus is reduced.

Description

technical field [0001] The invention relates to a cardiovascular interventional treatment device, in particular to an eluting stent for providing expansion support for a patient's cardiovascular system during percutaneous arterial interventional stent surgery. Background technique [0002] Cardiovascular disease has become one of the major diseases threatening human health. One of the most common cardiovascular diseases—coronary heart disease, referred to as coronary heart disease for short, refers to the abnormal lipid metabolism, the lipids in the blood are deposited on the original smooth arterial intima, forming a white plaque similar to atheroma. Plaques, called atherosclerotic lesions. Percutaneous arterial interventional stenting has become an important treatment. The development stages of stents are bare metal stents and drug eluting stents. The biggest problem with bare stents is intimal hyperplasia that leads to restenosis. The application of drug-eluting stent...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61L31/10A61L31/14A61L31/16
CPCA61L31/10A61L31/148A61L31/16A61L2300/416A61L2300/422A61L2300/608C08L67/04
Inventor 王进李娜李欣赵元聪冷永祥黄楠
Owner SOUTHWEST JIAOTONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap